Clinical Trial

A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

Study acronym: BELAMI
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The BELAMI trial is an open label, multicenter, phase 2 study for patients with MM who relapsed following BCMA-directed CAR-T cells or bispecific antibodies with a Phase Ib Safety run-in. The primary hypothesis of this study is that a combination of ADC targeting BCMA and CELMoD will be efficient for these patients.
Protocol Amendment History 1 change
critical Phase changed: Phase 2 -> Phase 1/2 2026-06-16
Trial Details
NCT Number NCT07612787
Lead Sponsor Centre Hospitalier Universitaire de Saint Etienne
Conditions Myeloma Multiple
Enrollment 44 participants
Start Date 2026-06-01
Primary Completion 2028-01-01 (estimated)
Study Completion 2031-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-15